The BioBox
The BioBox is a privately held California biotech company that develops and sells UCM-X, a topical cell-derived secretome product enriched with exosomes, distributed through domestic distributors to physicians, dermatologists, aestheticians, and consumers for skincare applications.
- Company typePrivate
- Founded2009
- HeadquartersCorona, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What The BioBox does
The BioBox, LLC is a privately held biotechnology company headquartered in Corona, California, founded in 2009 (with firmographic records also citing 2012). The company operates a cGMP-compliant manufacturing facility and a reference laboratory, and has spent approximately 15 years conducting research into the biology of cellular aging, with a focus on cell regeneration, rejuvenation, and repair using mesenchymal stem cell (MSC) science.
The company's commercial flagship product is UCM-X, a topical, organic, cell-derived secretome enriched with exosomes, collagen, elastin, and other bioactive proteins. The product is triple-filtered, characterized, and certified free of pathogenic viruses, and preclinical in-vitro studies have shown improved collagen and elastin concentrations in skin of 25- and 53-year-old users, with measured concentrations exceeding 580 ng/ml of hyaluronic acid and 28 ng/ml of elastin. Beyond the cosmetic UCM-X SKU, the company pursues a research pipeline covering natural killer (NK) cell-based immunotherapies, cell-based therapeutics for senescence, and IND-stage programs.
The BioBox monetizes UCM-X through a domestic distributor network targeting physicians, dermatologists, aestheticians, and their clients, supplemented by direct sales contact. Pricing is not publicly disclosed. The company holds patents (filed/pending) on stem cell technology for clinical applications and on cell-based therapeutics for senescence, and operates under cGMP, GTP for HCT/P, and GLP compliance regimes. It is a small organization with approximately 11 named team members spanning scientific R&D, regulatory/quality, and administrative functions, with no disclosed external funding or institutional investors.
The BioBox firmographics
Firmographics- Name
- The BioBox
- Legal name
- The BioBox, LLC
- Website
- https://thebiobox.com
- Company type
- Private
- Founded year
- 2009
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- The BioBox is a privately held California biotech company that develops and sells UCM-X, a topical cell-derived secretome product enriched with exosomes, distributed through domestic distributors to physicians, dermatologists, aestheticians, and consumers for skincare applications.
- Ownership category
- akta.pro rank
The BioBox industry classification
Industry- Product category
- Regenerative Skincare Biotechnology
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414), Toilet Preparation Manufacturing (325620), Pharmaceutical and Medicine Manufacturing (3254)
- SIC
- Biological Products, (No Disgnostic Substances) (2836), Perfumes, Cosmetics & Other Toilet Preparations (2844)
- akta.pro primary industry
- Dermocosmetics & Medical-Grade Skincare (CRABAAAF)
- akta.pro secondary industries
- Acellular/Decellularized Matrices & ECM Products (HLAAAGAF), Wound Healing & Skin Regeneration (advanced dressings, skin substitutes) (HLAAAGAG), Stem Cell–Based Regenerative Therapies (HLAAAGAA)
Keywords
Where The BioBox is headquartered
LocationHeadquarters
- HQ city
- Corona
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
The BioBox business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Operations, Supply Chain, Marketing or Sales, Infrastructure
Revenue model
- UCM-X Product Sales: Sale of topical cell-derived secretome product UCM-X to physicians, dermatologists, aestheticians, and consumers. Product is sold for cosmetic topical use as a skincare/anti-aging treatment.
Go-to-market motion1 record
Distribution channels2 records
Marketing channels1 record
The BioBox product offering
Product offeringCore offering
The BioBox develops, manufactures, and sells UCM-X, a topical, organic, cell-derived secretome product naturally enriched with exosomes, collagen, elastin, and other essential proteins derived from mesenchymal stem cells. UCM-X is positioned as a noninvasive skincare/anti-aging treatment used alongside cosmetic products or to enhance aesthetic procedures such as facials, microneedling, dermabrasion, and laser therapy, sold to physicians, dermatologists, aestheticians, and consumers.
Product overview
TheBioBox is a biotechnology company dedicated to improving health and wellness through research and development of cell-based products and a reference laboratory. For 15 years, scientists have been researching the biology of cellular aging with a focus on cell regeneration, rejuvenation, and repair. The company's main commercial product is UCM-X, a next-generation topical secretome/exosome product for skincare applications, targeting physicians, dermatologists, aestheticians, and their clients.
Differentiator
Problem solved
Functional benefit
Brands
- UCM-X: A topical, organic, cell-derived secretome product naturally enriched with exosomes, collagen, elastin, and other essential proteins designed to improve skin appearance by reducing acne scars, sunspots, fine lines, and wrinkles.
Products and services
- UCM-X A topical, organic, cell-derived secretome product naturally enriched with exosomes, collagen, elastin, and other essential proteins. Designed to improve the appearance of dull, damaged, and uneven skin by reducing acne scars, sunspots, fine lines, and wrinkles, and to help skin appear more radiant. Intended for use with skincare/cosmetic products or as a noninvasive addition to aesthetic procedures such as facials, microneedling, dermabrasion, and laser therapy. Manufactured in the U.S. under cGMP.
Quantifiable outcome
- Preclinical studies demonstrated significant improvement in collagen and elastin concentrations in skin of 25- and 53-year-old UCM-X users
- +2 more outcomes
Companies that use The BioBox
Customer profileSegments3 records
Ideal customer profiles3 records
The BioBox technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
The BioBox partnerships and signals
Strategic signalScale indicators2 records
Recent moves5 records
Expansion highlights6 records
The BioBox competitors and assessment
Company assessmentDirect peers
- Kimera Labs: Kimera Labs develops exosome-based regenerative skincare products distributed through medical and aesthetic professionals. Directly comparable to TheBioBox in technology (MSC-derived exosomes/secretome), product category (topical regenerative skincare), and go-to-market (physicians/aestheticians).
- BENEV Company: BENEV is an established exosome and growth-factor skincare brand sold exclusively through physicians, med-spas, and licensed skincare professionals. Closely comparable in distribution model and product positioning to UCM-X.
- ExoCoBio: ExoCoBio is a global exosome-focused biotechnology company commercializing stem-cell-derived exosome cosmetics and skincare through professional channels. Comparable in core technology (exosome cosmeceuticals) and aesthetic-medicine channel.
Emerging players
- Elevai Labs: Elevai Labs develops exosome-based skincare serums targeted at medical aesthetic practices and providers. Comparable technology platform (stem-cell-derived exosomes for topical skin rejuvenation) with a similar early-stage commercial profile.
- Pluristem Therapeutics: Pluristem develops placenta-derived cell therapy products for regenerative indications including wound healing. Comparable in cell-based regenerative platform and cGMP biomanufacturing, though at clinical-stage scale.
- AgeX Therapeutics: AgeX is a biotechnology company focused on cellular aging and regenerative medicine, including stem-cell-derived therapeutics targeting age-related decline. Directly comparable research focus (biology of cellular aging) and technology base to TheBioBox's underlying R&D.
Broad incumbents
- Organogenesis: Organogenesis is a publicly-traded regenerative medicine company producing living-cell and skin-substitute therapies for wound healing and surgical applications. Overlaps with TheBioBox in regenerative skin biology and cGMP cell-based manufacturing, though at much larger scale and with FDA-approved products.
- Vericel Corporation: Vericel develops autologous cell therapies for sports medicine and severe burn treatment using cultured cell-based products. Comparable in cell-therapy manufacturing, cGMP operations, and regenerative-medicine commercial pathways.
- SkinCeuticals: SkinCeuticals is an established physician-channel skincare brand owned by L'Oréal, positioned in the 'medical-grade' skincare segment that TheBioBox's UCM-X also targets. Comparable in distribution (dermatologists, plastic surgeons, medical spas) rather than technology.
- SkinMedica (Allergan Aesthetics): SkinMedica is a major physician-dispensed skincare brand under Allergan Aesthetics, with growth-factor and anti-aging product lines targeting the same dermatology/aesthetic practice channel as UCM-X.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks7 records
Key highlights6 records
Customer concentration
The BioBox social profiles
Digital presenceThe BioBox compliance and trust
Trust signalCompliance2 records
The BioBox financial estimates
Financial estimateRevenue estimate
Valuation estimate
The BioBox leadership team
Management profileNumber of profiles
Profiles12 records
The BioBox funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
The BioBox M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about The BioBox
What does The BioBox do?
The BioBox develops, manufactures, and sells UCM-X, a topical, organic, cell-derived secretome product naturally enriched with exosomes, collagen, elastin, and other essential proteins derived from mesenchymal stem cells. UCM-X is positioned as a noninvasive skincare/anti-aging treatment used alongside cosmetic products or to enhance aesthetic procedures such as facials, microneedling, dermabrasion, and laser therapy, sold to physicians, dermatologists, aestheticians, and consumers.
Is The BioBox a public or private company?
The BioBox is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was The BioBox founded?
The BioBox was founded in 2009. It employs 11 to 50 people.
Where is The BioBox based?
The BioBox is headquartered in Corona, United States, in the North America region.
How does The BioBox make money?
One revenue line is on record: UCM-X Product Sales.
Who are The BioBox's main competitors?
Direct peers on record are Kimera Labs, BENEV Company and ExoCoBio. Emerging players are Elevai Labs, Pluristem Therapeutics and AgeX Therapeutics. Broad incumbents are Organogenesis, Vericel Corporation, SkinCeuticals and SkinMedica (Allergan Aesthetics).
Does The BioBox have an API?
No public API is recorded for The BioBox.
What industry is The BioBox in?
The BioBox's product category is Regenerative Skincare Biotechnology. Its primary akta.pro industry code is CRABAAAF, Dermocosmetics & Medical-Grade Skincare, with a secondary code of HLAAAGAF, Acellular/Decellularized Matrices & ECM Products. Its NAICS code is 325414 and its SIC code is 2836.